Border measures for IP enforcement in biotechnology

Introduction

Border measures for intellectual property (IP) enforcement refer to legal procedures that allow customs authorities to prevent the import or export of goods suspected of infringing intellectual property rights. These measures help protect patent holders, trademark owners, copyright holders and other rights holders from the international movement of counterfeit, pirated or infringing products.

In biotechnology, border enforcement is particularly important because pharmaceutical products, vaccines, diagnostic kits, genetically modified materials, laboratory equipment, biological samples and biotechnology-related inventions frequently move across national borders. Unauthorised importation or exportation of such products may violate intellectual property rights and create risks to public health, research integrity and commercial interests.

For example, a company may manufacture a patented biological drug, while another manufacturer attempts to import an unauthorised product using the protected invention. Customs authorities may be asked to examine the shipment and take appropriate action under applicable intellectual property and customs laws.

However, border enforcement must balance intellectual property protection with access to affordable medicines, legitimate international trade, public health requirements and international obligations.

Legal framework governing border measures in India

1. Customs Act, 1962

The Customs Act, 1962 provides the principal legal framework for controlling the import and export of goods into and out of India.

Important provisions include:

Section 11: Empowers the Central Government to prohibit imports or exports of specified goods for purposes recognised by the Act.

Section 111: Provides for confiscation of improperly imported goods in specified circumstances.

Section 113: Provides for confiscation of goods attempted to be improperly exported.

Section 110: Deals with seizure of goods liable to confiscation.

Section 124: Requires a notice and an opportunity of hearing before confiscation or penalty, subject to the statutory framework.

These provisions enable customs authorities to take action against goods that violate applicable import or export restrictions, including relevant intellectual property requirements.

2. Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007

The Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007 were introduced under the Customs Act, 1962 to establish procedures for enforcing intellectual property rights at the border.

The Rules cover specified intellectual property rights, including:

Patents.

Trademarks.

Copyright.

Geographical indications.

Designs.

Semiconductor integrated circuit layout designs.

The Rules allow eligible rights holders to give notice to customs authorities requesting action against imported goods suspected of infringing their intellectual property rights.

A rights holder must provide relevant information and supporting documents to enable customs authorities to identify potentially infringing consignments.

The Rules also provide procedures for examination, suspension of clearance, notice to interested parties and determination of infringement.

Important limitation: The Rules primarily address imported goods. They should not automatically be treated as a comprehensive customs procedure for every category of exported biotechnology material.

3. Patents Act, 1970

The Patents Act, 1970 protects eligible biotechnology inventions, subject to statutory exclusions and patentability requirements.

Section 48: Defines the rights of patentees, including the right to prevent unauthorised making, using, offering for sale, selling or importing patented products in India.

Section 104: Deals with the jurisdiction of courts in patent infringement suits.

Section 107: Provides defences available in patent infringement proceedings.

Section 107A: Provides certain exceptions, including specified acts relating to regulatory submissions and parallel importation.

Section 107A is particularly important for pharmaceutical and biotechnology products because it protects certain activities undertaken to obtain regulatory approval and permits specified parallel imports.

4. Trademarks Act, 1999

The Trademarks Act protects brand names, logos and product identifiers used by biotechnology and pharmaceutical companies.

Sections 29 and 30 deal with trademark infringement and limitations on trademark rights. Customs authorities may act against imported counterfeit products bearing deceptively similar pharmaceutical or biotechnology brands under the applicable border-enforcement framework.

5. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes international standards for intellectual property protection.

Important provisions include:

Article 51: Requires members to provide procedures enabling rights holders to request suspension of customs release of suspected counterfeit trademark and pirated copyright goods.

Article 52: Establishes evidentiary requirements for applications.

Article 53: Provides rules concerning security or equivalent assurance.

Article 54: Requires notification of suspension.

Article 55: Addresses the duration of suspension.

Article 58: Deals with action by customs authorities.

Article 60: Allows members to exclude small quantities of non-commercial goods from border procedures.

A significant distinction is that TRIPS Article 51 makes border procedures mandatory for specified counterfeit trademark and pirated copyright goods. It does not impose the same general obligation for every patent infringement involving biotechnology products.

Application of border measures in biotechnology

1. Protection of patented pharmaceutical products

Biotechnology companies invest substantial resources in developing biological medicines, vaccines and therapeutic proteins. Patent protection enables them to prevent unauthorised commercial exploitation of patented inventions.

Where imported goods are suspected of infringing a valid Indian patent, the patentee may seek appropriate legal remedies. Customs intervention must operate within the applicable statutory framework, including the IPR Enforcement Rules and judicial procedures.

2. Prevention of counterfeit medicines

Counterfeit pharmaceutical products may carry false brand names, misleading packaging or unauthorised product labels. Customs authorities can examine suspicious consignments and take appropriate action under intellectual property and other applicable laws.

This protects manufacturers and helps prevent unsafe or falsely represented products from entering the market.

3. Protection of biotechnology trademarks

Pharmaceutical companies often depend on established trademarks to distinguish genuine products from unauthorised copies. Customs enforcement can help identify imported products carrying counterfeit marks.

This is particularly important for vaccines, diagnostic kits, laboratory reagents and specialised biological medicines.

4. Protection of biotechnology research materials

Biotechnology companies may seek to protect proprietary research products, patented laboratory technologies and specialised commercial materials. Border enforcement can assist where the imported goods fall within the scope of a protected intellectual property right.

However, biological samples, genetic resources and research materials are not automatically protected by patents or trademarks merely because they are commercially valuable. Their movement may also be regulated under biodiversity, biosafety, quarantine and export-control laws.

5. Parallel imports and regulatory exceptions

Border enforcement must not become a mechanism for preventing legitimate trade. Section 107A of the Patents Act, 1970 recognises specified regulatory and parallel-import exceptions.

Therefore, customs authorities and courts must distinguish genuine infringement from legally permitted imports.

Procedure for customs enforcement in India

The general process under the 2007 Rules involves the following stages:

Registration of intellectual property: The rights holder submits the prescribed notice and supporting documents to the customs authority.

Identification of suspicious goods: Customs authorities examine consignments that may contain infringing products.

Suspension of clearance: Where the prescribed conditions are met, clearance may be suspended.

Notification: The relevant parties are informed in accordance with the Rules.

Examination and determination: The rights holder and importer may provide information and evidence concerning the suspected infringement.

Disposal of infringing goods: Goods determined to infringe may be confiscated or otherwise dealt with under the applicable legal procedure.

The rights holder may also pursue civil proceedings where necessary.

Important case laws

There are relatively few Indian judgments specifically concerning customs enforcement of biotechnology patents. However, the following decisions provide important principles concerning pharmaceutical patents, parallel imports and intellectual property enforcement.

1. Bayer Corporation v. Union of India (2014)

The Delhi High Court considered issues relating to the importation of patented pharmaceutical products and the operation of Section 107A of the Patents Act, 1970.

The dispute concerned the interpretation of the statutory provisions governing parallel imports and the conditions under which importation may be legally permitted.

Relevance: The decision is important for understanding the relationship between patent enforcement and legitimate pharmaceutical imports. It demonstrates that border enforcement must respect statutory exceptions and cannot automatically treat every import of a patented product as infringement.

2. Bayer Corporation v. Union of India (2019)

The Delhi High Court examined aspects of patent enforcement and the regulatory framework concerning the importation of pharmaceutical products.

The litigation highlighted the importance of interpreting Section 107A in accordance with its statutory language and the conditions governing permitted imports.

Relevance: The judgment illustrates the need to balance patent-holder rights with lawful access to pharmaceutical products and the statutory exceptions available to importers.

3. Novartis AG v. Union of India (2013)

The Supreme Court considered the patentability of a modified form of an existing pharmaceutical substance under Section 3(d) of the Patents Act, 1970.

The Court rejected the patent application because the claimed invention did not satisfy the statutory requirement concerning enhanced therapeutic efficacy.

Relevance: Although not a customs case, the judgment establishes that border enforcement depends on the existence of legally enforceable intellectual property rights. A company cannot rely on customs measures to enforce a patent claim that does not satisfy Indian patentability requirements.

4. Roche Products (India) Pvt. Ltd. v. Drugs Controller General of India (2015)

The Delhi High Court considered issues involving pharmaceutical patents and regulatory approvals.

The dispute illustrates the relationship between intellectual property protection and the regulatory framework governing pharmaceutical products.

Relevance: It demonstrates that patent enforcement and regulatory approval are distinct legal questions. Customs authorities must consider the actual intellectual property rights involved rather than assuming that regulatory approval alone establishes patent infringement.

5. Entertainment Network (India) Ltd. v. Super Cassette Industries Ltd. (2008)

The Supreme Court considered copyright licensing and the balance between intellectual property rights and public interest.

Relevance: Although the case did not concern biotechnology or customs enforcement, it illustrates that intellectual property rights operate within a wider legal framework that may require balancing private rights with public interest.

Challenges in border enforcement for biotechnology

1. Scientific complexity: Customs officials may find it difficult to distinguish between genuine and allegedly infringing biological products without expert technical assistance.

2. Patent interpretation: Biotechnology patents frequently involve complex claims concerning biological processes, engineered materials and pharmaceutical formulations.

3. Public health concerns: Excessive restrictions on legitimate pharmaceutical imports may affect access to essential medicines and vaccines.

4. Parallel imports: Authorities must distinguish unauthorised imports from imports permitted under Section 107A of the Patents Act.

5. International differences: Patent protection and regulatory approvals may differ between countries, creating difficulties in cross-border enforcement.

6. Perishable biological materials: Certain biological products require controlled temperatures and specialised storage. Delayed customs clearance may affect product quality and safety.

7. Coordination between authorities: Customs officials may need assistance from patent offices, drug regulators, biosafety authorities and scientific experts.

Conclusion

Border measures for intellectual property enforcement in biotechnology are important for preventing the international movement of counterfeit, pirated and infringing products. In India, the Customs Act, 1962, Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007, Patents Act, 1970 and Trademarks Act, 1999 provide the principal domestic framework.

The TRIPS Agreement establishes international standards for customs enforcement, while Indian judicial decisions concerning pharmaceutical patents and parallel imports clarify the limits of intellectual property protection.

Effective border enforcement must protect legitimate biotechnology inventions and commercial interests without obstructing lawful pharmaceutical trade, regulatory exceptions or public access to essential medicines. A balanced system requires scientific expertise, accurate identification of infringing products, transparent procedures and coordination between customs authorities and intellectual property regulators.